Position history for CITADEL ADVISORS LLC's holdings in MoonLake Immunotherapeutics
CITADEL ADVISORS LLC holds 380,890 shares of MLTX (MoonLake Immunotherapeutics), worth $5M as of 2025-Q4. The position was increased (++672.1% shares). MLTX represents 0.0% of CITADEL ADVISORS LLC's portfolio.
Current Value
$5M
Current Shares
380,890
Total Value Change
-$111M
Total Shares Change
-1.9M
Other major holders of MLTX: FMR LLC, Avoro Capital Advisors LLC
Increased |
| 380,890 |
+672.1% |
| $5M |
| 0.0% |
| $13.21 |
43 |
| 2025-Q3 | Decreased | 49,334 | -97.0% | $353,725 | 0.0% | $6.24 | 0 |
| 2025-Q2 | Increased | 1.7M | +13.2% | $79M | 0.0% | $47.52 | 34 |
| 2025-Q1 | Decreased | 1.5M | -32.4% | $57.8M | 0.0% | $39.86 | 0 |
| 2024-Q4 | Decreased | 2.2M | -5.9% | $118.4M | 0.0% | $53.02 | 0 |
| 2024-Q3 | Increased | 2.3M | +2.5% | $117.1M | 0.0% | $49.40 | 31 |
| 2024-Q2 | Decreased | 2.3M | -1.9% | $99.6M | 0.0% | $43.97 | 0 |
| 2024-Q1 | Increased | 2.3M | +15.0% | $116M | 0.0% | $50.23 | 34 |